Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with investment in Apica
Mandate

Vinge advises Industrifonden in connection with investment in Apica

June 29, 2011

Vinge has advised Stiftelsen Industrifonden in connection with an SEK 10 million investment in Apica. Apica tests, analyses, monitors and improves the performance of websites. The existing investor, KTH Chalmers Capital also participated in the issue which amounts in total to SEK 15 million. The funds will be used to finance the launch of Apica’s services in the US. Apica was founded in 2005 and has its head office in Stockholm and sales offices in Great Britain and the US.

Vinge’s team consisted of project manager Johan Larsson together with Tina Hård and Malin Buch. Johan Winnerbald was the responsible partner.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024